Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression

Carcinogenesis

Volumn 36, Issue , 2015, Pages S2-S18

  Nahta, Rita ^h   Al Mulla, Fahd ^a   Al Temaimi, Rabeah ^a   Amedei, Amedeo ^b   Andrade Vieira, Rafaela ^c   Bay, Sarah ^d   Brown, Dustin G ^e   Calaf, Gloria M ^f,g   Castellino, Robert C ^h   Cohen Solal, Karine A ⁱ   Colacci, Annamaria ^j   Cruickshanks, Nichola ^k   Dent, Paul ^k   Di Fiore, Riccardo ^l   Forte, Stefano ^m   Goldberg, Gary S ⁿ   Hamid, Roslida A ^o   Krishnan, Harini ⁿ   Laird, Dale W ^p   Lasfar, Ahmed ^q   Marignani, Paola A ^c   Memeo, Lorenzo ^m   Mondello, Chiara ^r   Naus, Christian C ^s   Ponce Cusi, Richard ^g   Raju, Jayadev ^t   Roy, Debasish ^u   Roy, Rabindra ^v   Ryan, Elizabeth P ^e   Salem, Hosni K ^w   Ivana Scovassi, A ^r   Singh, Neetu ^x   Vaccari, Monica ^j   Vento, Renza ^l,y   Vondráček, Jan ^z   Wade, Mark ^aa   Woodrick, Jordan ^v   Bisson, William H ^ab   more..

^a KUWAIT UNIVERSITY   (Kuwait)

^b UNIVERSITY OF FLORENCE   (Italy)

^c DALHOUSIE UNIVERSITY   (Canada)

^d EMORY UNIVERSITY   (United States)

^e Veterinary Dentistry and Oral Surgery   (United States)

^f Department of Medicine   (United States)

^g UNIVERSIDAD DE TARAPACÁ   (Chile)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^j Center for Envirn Carcinogenesis and Risk Assessment Envirn Protection Health Prevention Agency   (Italy)

^k VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^l UNIVERSITY OF PALERMO   (Italy)

^m Department of Medical Oncology   (Italy)

ⁿ ROWAN UNIVERSITY   (United States)

^o Putra Malaysia University   (Malaysia)

^p UNIVERSITY OF WESTERN ONTARIO   (Canada)

^q RUTGERS UNIVERSITY   (United States)

^r CNR   (Italy)

^s UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^t TOXICOLOGY RESEARCH DIVISION   (Canada)

^u CITY UNIVERSITY OF NEW YORK   (United States)

^v GEORGETOWN UNIVERSITY   (United States)

^w CAIRO UNIVERSITY   (Egypt)

^x KING GEORGE'S MEDICAL UNIVERSITY   (India)

^y Temple University   (United States)

^z INSTITUTE OF BIOPHYSICS   (Czech Republic)

^aa ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^ab OREGON STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENVIRONMENTAL CHEMICAL; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSFORMING GROWTH FACTOR BETA; 4,4' ISOPROPYLIDENEDIPHENOL; CHLORPHENOTANE; FOLPET; GAP JUNCTION PROTEIN; HERBICIDE; TRIAZINE; DANGEROUS GOODS;

CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE PROGRESSION; CONTACT INHIBITION; GAP JUNCTION; HUMAN; IMMUNE EVASION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANGIOGENESIS; CELL DEATH; METABOLISM; MOLECULAR MECHANICS; TUMOR ESCAPE; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; DANGEROUS GOODS; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; ENVIRONMENTAL EXPOSURE; HAZARDOUS SUBSTANCES; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84937697813     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv028     Document Type: Review

References (258)

1. Lee, W. et al. (1994) Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol., 1, 877-890.
2. Bieging, K.T. et al. (2012) Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol., 22, 97-106.
3. Goh, A.M. et al. (2011) The role of mutant p53 in human cancer. J. Pathol., 223, 116-126.
4. Kussie, P.H. et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953.
5. Popowicz, G.M. et al. (2008) Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle, 7, 2441-2443.
6. Pant, V. et al. (2011) Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc. Natl. Acad. Sci. USA, 108, 11995-12000.
7. Huang, L. et al. (2011) The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc. Natl. Acad. Sci. USA, 108, 12001-12006.
8. Gu, J. et al. (2002) Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem., 277, 19251-19254.
9. Ray-Coquard, I. et al. (2012) Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol., 13, 1133-1140.
10. Wade, M. et al. (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer, 13, 83-96.
11. Smith, J. et al. (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res., 108, 73-112.
12. Bartek, J. et al. (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3, 421-429.
13. Jin, J. et al. (2008) Differential roles for checkpoint kinases in DNA damage- dependent degradation of the Cdc25A protein phosphatase. J. Biol. Chem., 283, 19322-19328.
14. Zhou, B.B. et al. (2003) Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol. Ther., 2(4 Suppl 1), S16-S22.
15. Yadavilli, S. et al. (2009) Mechanism of diepoxybutane-induced p53 regulation in human cells. J. Biochem. Mol. Toxicol., 23, 373-386.
16. Giardiello, F.M. et al. (1987) Increased risk of cancer in the Peutz-Jeghers syndrome. N. Engl. J. Med., 316, 1511-1514.
17. Avizienyte, E. et al. (1999) LKB1 somatic mutations in sporadic tumors. Am. J. Pathol., 154, 677-681.
18. Chen, R.W. et al. (1999) PTEN and LKB1 genes in laryngeal tumours. J. Med. Genet., 36, 943-944.
19. Guldberg, P. et al. (1999) Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene, 18, 1777-1780.
20. Zeng, P.Y. et al. (2006) LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res., 66, 10701-10708.
21. Scott, K.D. et al. (2007) LKB1 catalytically deficient mutants enhance cyclin D1 expression. Cancer Res., 67, 5622-5627.
22. Nath-Sain, S. et al. (2009) LKB1 catalytic activity contributes to estrogen receptor alpha signaling. Mol. Biol. Cell, 20, 2785-2795.
23. Gurumurthy, S. et al. (2008) LKB1 deficiency sensitizes mice to carcinogen- induced tumorigenesis. Cancer Res., 68, 55-63.
24. Ratovitski, E.A. (2010) LKB1/PEA3/ΔNp63 pathway regulates PTGS-2 (COX-2) transcription in lung cancer cells upon cigarette smoke exposure. Oxid. Med. Cell. Longev., 3, 317-324.
25. Pfeifer, G.P. et al. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene, 21, 7435-7451.
26. Hussain, S.P. et al. (2001) Mutability of p53 hotspot codons to benzo(a) pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res., 61, 6350-6355.
27. Jiang, Y. et al. (2007) Ataxia-telangiectasia mutated expression is associated with tobacco smoke exposure in esophageal cancer tissues and benzo[a]pyrene diol epoxide in cell lines. Int. J. Cancer, 120, 91-95.
28. Ozturk, M. (1991) p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, 338, 1356-1359.
29. Hamid, A.S. et al. (2013) Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol. Lett., 5, 1087-1092.
30. Dairkee, S.H. et al. (2013) Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. Carcinogenesis, 34, 703-712.
31. Cohen, S.M. et al. (2010) Carcinogenic mode of action of folpet in mice and evaluation of its relevance to humans. Crit. Rev. Toxicol., 40, 531-545.
32. Santucci, M.A. et al. (2003) Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides. Environ. Mol. Mutagen., 41, 315-321.
33. Kazantseva, Y.A. et al. (2013) Dichlorodiphenyltrichloroethane technical mixture regulates cell cycle and apoptosis genes through the activation of CAR and ERα in mouse livers. Toxicol. Appl. Pharmacol., 271, 137-143.
34. Pariseau, J. et al. (2009) Potential link between exposure to fungicides chlorothalonil and mancozeb and haemic neoplasia development in the soft-shell clam Mya arenaria: a laboratory experiment. Mar. Pollut. Bull., 58, 503-514.
35. Pariseau, J. et al. (2011) Effects of pesticide compounds (chlorothalonil and mancozeb) and benzo[a]pyrene mixture on aryl hydrocarbon receptor, p53 and ubiquitin gene expression levels in haemocytes of soft-shell clams (Mya arenaria). Ecotoxicology, 20, 1765-1772.
36. Liu, Z. et al. (2005) p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res., 65, 2583-2587.
37. Wang, J.Y. et al. (1994) The retinoblastoma tumor suppressor protein. Adv. Cancer Res., 64, 25-85.
38. Brown, M. et al. (1991) Fidelity of mitotic chromosome transmission. Cold Spring Harb. Symp. Quant. Biol., 56, 359-365.
39. Weinberg, R.A. (1995) The retinoblastoma protein and cell cycle control. Cell, 81, 323-330.
40. Weintraub, S.J. et al. (1995) Mechanism of active transcriptional repression by the retinoblastoma protein. Nature, 375, 812-815.
41. Lundberg, A.S. et al. (1998) Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol., 18, 753-761.
42. Kiyokawa, H. et al. (1994) Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Mol. Cell. Biol., 14, 7195-7203.
43. An, H.X. et al. (1999) Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am. J. Pathol., 154, 113-118.
44. Papp, T. et al. (1999) Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J. Med. Genet., 36, 610-614.
45. Konishi, N. et al. (2002) Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am. J. Pathol., 160, 1207-1214.
46. Nielsen, G.P. et al. (1998) CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am. J. Pathol., 153, 159-163.
47. Myong, N.H. (2008) Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients. Cancer Res. Treat., 40, 45-52.
48. Pietruszewska, W. et al. (2008) Loss of heterozygosity for Rb locus and pRb immunostaining in laryngeal cancer: a clinicopathologic, molecular and immunohistochemical study. Folia Histochem. Cytobiol., 46, 479-485.
49. Heck, J.E. et al. (2013) Retinoblastoma and ambient exposure to air toxics in the perinatal period. J. Expo. Sci. Environ. Epidemiol, 25, 182-186.
50. Wiseman, R.W. et al. (1994) Allelotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. Proc. Natl. Acad. Sci. USA, 91, 3759-3763.
51. Jeong, J.B. et al. (2010) 2-Methoxy-4-vinylphenol can induce cell cycle arrest by blocking the hyper-phosphorylation of retinoblastoma protein in benzo[a]pyrene-treated NIH3T3 cells. Biochem. Biophys. Res. Commun., 400, 752-757.
52. Bastide, K. et al. (2009) Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors. Lung Cancer, 63, 348-353.
53. Torres-Durán, M. et al. (2014) Residential radon and lung cancer in never smokers. A systematic review. Cancer Lett., 345, 21-26.
54. Li, Y. et al. (2011) Up-regulation of cyclin D1 by JNK1/c-Jun is involved in tumorigenesis of human embryo lung fibroblast cells induced by a low concentration of arsenite. Toxicol. Lett., 206, 113-120.
55. Ikushima, H. et al. (2010) TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer, 10, 415-424.
56. Massagué, J. (2012) TGFβ signalling in context. Nat. Rev. Mol. Cell Biol., 13, 616-630.
57. Lasfar, A. et al. (2010) Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis, 31, 1710-1717.
58. Matsuzaki, K. (2011) Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis, 32, 1578-1588.
59. Yang, S. et al. (2008) EGF antagonizes TGF-beta-induced tropoelastin expression in lung fibroblasts via stabilization of Smad corepressor TGIF. Am. J. Physiol. Lung Cell. Mol. Physiol., 295, L143-L151.
60. Lo, R.S. et al. (2001) Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. EMBO J., 20, 128-136.
61. Dai, C. et al. (2004) Hepatocyte growth factor antagonizes the profibrotic action of TGF-beta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGIF. J. Am. Soc. Nephrol., 15, 1402-1412.
62. Tan, R. et al. (2007) Molecular basis for the cell type specific induction of SnoN expression by hepatocyte growth factor. J. Am. Soc. Nephrol., 18, 2340-2349.
63. Kuang, C. et al. (2006) In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proc. Natl. Acad. Sci. U. S. A., 103, 1858-1863.
64. Luwor, R.B. et al. (2013) Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo. Oncogene, 32, 2433-2441.
65. Chi, X.Z. et al. (2005) RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol. Cell. Biol., 25, 8097-8107.
66. Yano, T. et al. (2006) The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor betainduced apoptosis. Mol. Cell. Biol., 26, 4474-4488.
67. Ito, K. et al. (2011) Loss of Runx3 is a key event in inducing precancerous state of the stomach. Gastroenterology, 140, 1536-46.e8.
68. Goh, Y.M. et al. (2010) Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm. J. Biol. Chem., 285, 10122-10129.
69. Seoane, J. et al. (2004) Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell, 117, 211-223.
70. Gomis, R.R. et al. (2006) C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell, 10, 203-214.
71. Brunet, A. et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96, 857-868.
72. Azar, R. et al. (2009) 4E-BP1 is a target of Smad4 essential for TGFbetamediated inhibition of cell proliferation. EMBO J., 28, 3514-3522.
73. Bailey, K.A. et al. (2012) Transcriptional Modulation of the ERK1/2 MAPK and NF-κB Pathways in Human Urothelial Cells After Trivalent Arsenical Exposure: Implications for Urinary Bladder Cancer. J. Can. Res. Updates, 1, 57-68.
74. Germolec, D.R. et al. (1996) Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol. Appl. Pharmacol., 141, 308-318.
75. Allison, P. et al. (2013) Disruption of canonical TGFβ-signaling in murine coronary progenitor cells by low level arsenic. Toxicol. Appl. Pharmacol., 272, 147-153.
76. Goodenough, D.A. et al. (1996) Connexins, connexons, and intercellular communication. Annu. Rev. Biochem., 65, 475-502.
77. Laird, D.W. (2006) Life cycle of connexins in health and disease. Biochem. J., 394, 527-543.
78. Cronier, L. et al. (2009) Gap junctions and cancer: new functions for an old story. Antioxid. Redox Signal., 11, 323-338.
79. Naus, C.C. et al. (2010) Implications and challenges of connexin connections to cancer. Nat. Rev. Cancer, 10, 435-441.
80. Loewenstein, W.R. et al. (1967) Intercellular communication and tissue growth. I. Cancerous growth. J. Cell Biol., 33, 225-234.
81. Rose, B. et al. (1993) Gap-junction protein gene suppresses tumorigenicity. Carcinogenesis, 14, 1073-1075.
82. Naus, C.C. et al. (1992) In vivo growth of C6 glioma cells transfected with connexin43 cDNA. Cancer Res., 52, 4208-4213.
83. Zhu, D. et al. (1991) Transfection of C6 glioma cells with connexin 43 cDNA: analysis of expression, intercellular coupling, and cell proliferation. Proc. Natl. Acad. Sci. USA, 88, 1883-1887.
84. Leithe, E. et al. (2006) Downregulation of gap junctions in cancer cells. Crit. Rev. Oncog., 12, 225-256.
85. Mesnil, M. (2002) Connexins and cancer. Biol. Cell, 94, 493-500.
86. Yamasaki, H. et al. (1999) Connexins in tumour suppression and cancer therapy. Novartis Found. Symp., 219, 241-254.
87. Moennikes, O. et al. (1999) The effect of connexin32 null mutation on hepatocarcinogenesis in different mouse strains. Carcinogenesis, 20, 1379-1382.
88. King, T.J. et al. (2004) The gap junction protein connexin32 is a mouse lung tumor suppressor. Cancer Res., 64, 7191-7196.
89. King, T.J. et al. (2004) Mice deficient for the gap junction protein Connexin32 exhibit increased radiation-induced tumorigenesis associated with elevated mitogen-activated protein kinase (p44/Erk1, p42/ Erk2) activation. Carcinogenesis, 25, 669-680.
90. Plante, I. et al. (2011) Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease. Oncogene, 30, 1681-1692.
91. McLachlan, E. et al. (2006) Connexins act as tumor suppressors in three-dimensional mammary cell organoids by regulating differentiation and angiogenesis. Cancer Res., 66, 9886-9894.
92. Evans, W.H. et al. (2006) The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem. J., 397, 1-14.
93. Kandouz, M. et al. (2010) Gap junctions and connexins as therapeutic targets in cancer. Expert Opin. Ther. Targets, 14, 681-692.
94. Decrock, E. et al. (2009) Connexin 43 hemichannels contribute to the propagation of apoptotic cell death in a rat C6 glioma cell model. Cell Death Differ., 16, 151-163.
95. Vinken, M. et al. (2006) Connexins and their channels in cell growth and cell death. Cell. Signal., 18, 592-600.
96. Ito, A. et al. (2000) A role for heterologous gap junctions between melanoma and endothelial cells in metastasis. J. Clin. Invest., 105, 1189-1197.
97. Stoletov, K. et al. (2013) Role of connexins in metastatic breast cancer and melanoma brain colonization. J. Cell Sci., 126(Pt 4), 904-913.
98. Sin, W.C. et al. (2012) Opposing roles of connexin43 in glioma progression. Biochim. Biophys. Acta, 1818, 2058-2067.
99. Duffy, H.S. et al. (2006) Cardiac connexins: genes to nexus. Adv. Cardiol., 42, 1-17.
100. Meyer, R.A. et al. (1992) Inhibition of gap junction and adherens junction assembly by connexin and A-CAM antibodies. J. Cell Biol., 119, 179-189.
101. Wei, C.J. et al. (2005) Connexin43 associated with an N-cadherin-containing multiprotein complex is required for gap junction formation in NIH3T3 cells. J. Biol. Chem., 280, 19925-19936.
102. Matsuuchi, L. et al. (2012) Gap junction proteins on the move: connexins, the cytoskeleton and migration. Biochim. Biophys. Acta, 1828, 94-108.
103. Ruch, R.J. et al. (2001) Gap-junction communication in chemical carcinogenesis. Drug Metab. Rev., 33, 117-124.
104. Yamasaki, H. (1996) Role of disrupted gap junctional intercellular communication in detection and characterization of carcinogens. Mutat. Res., 365, 91-105.
105. Rosenkranz, H.S. et al. (2000) Exploring the relationship between the inhibition of gap junctional intercellular communication and other biological phenomena. Carcinogenesis, 21, 1007-1011.
106. Bager, Y. et al. (1997) Altered function, localization and phosphorylation of gap junctions in rat liver epithelial, IAR 20, cells after treatment with PCBs or TCDD. Environ. Toxicol. Pharmacol., 3, 257-266.
107. Hemming, H. et al. (1991) Inhibition of dye transfer in rat liver WB cell culture by polychlorinated biphenyls. Pharmacol. Toxicol., 69, 416-420.
108. Kang, K.S. et al. (1996) Inhibition of gap junctional intercellular communication in normal human breast epithelial cells after treatment with pesticides, PCBs, and PBBs, alone or in mixtures. Environ. Health Perspect., 104, 192-200.
109. Ruch, R.J. et al. (1986) Effects of tumor promoters, genotoxic carcinogens and hepatocytotoxins on mouse hepatocyte intercellular communication. Cell Biol. Toxicol., 2, 469-483.
110. Swierenga, S.H. et al. (1990) Effects on intercellular communication in human keratinocytes and liver-derived cells of polychlorinated biphenyl congeners with differing in vivo promotion activities. Carcinogenesis, 11, 921-926.
111. Vinken, M. et al. (2009) Gap junctional intercellular communication as a target for liver toxicity and carcinogenicity. Crit. Rev. Biochem. Mol. Biol., 44, 201-222.
112. Rivedal, E. et al. (2003) Supplemental role of the Ames mutation assay and gap junction intercellular communication in studies of possible carcinogenic compounds from diesel exhaust particles. Arch. Toxicol., 77, 533-542.
113. Krutovskikh, V.A. et al. (1995) Inhibition of rat liver gap junction intercellular communication by tumor-promoting agents in vivo. Association with aberrant localization of connexin proteins. Lab. Invest., 72, 571-577.
114. Rutten, A.A. et al. (1988) Effect of retinol and cigarette-smoke condensate on dye-coupled intercellular communication between hamster tracheal epithelial cells. Carcinogenesis, 9, 315-320.
115. Roemer, E. et al. (2013) Characterization of a gap-junctional intercellular communication (GJIC) assay using cigarette smoke. Toxicol. Lett.
116. Baker, T.K. et al. (1995) Inhibition of gap junctional intercellular communication by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in rat hepatocytes. Carcinogenesis, 16, 2321-2326.
117. Herrmann, S. et al. (2002) Indolo[3,2-b]carbazole inhibits gap junctional intercellular communication in rat primary hepatocytes and acts as a potential tumor promoter. Carcinogenesis, 23, 1861-1868.
118. Mally, A. et al. (2002) Non-genotoxic carcinogens: early effects on gap junctions, cell proliferation and apoptosis in the rat. Toxicology, 180, 233-248.
119. Plante, I. et al. (2002) Decreased gap junctional intercellular communication in hexachlorobenzene-induced gender-specific hepatic tumor formation in the rat. Carcinogenesis, 23, 1243-1249.
120. De Maio, A. et al. (2000) Interruption of hepatic gap junctional communication in the rat during inflammation induced by bacterial lipopolysaccharide. Shock, 14, 53-59.
121. Cowles, C. et al. (2007) Different mechanisms of modulation of gap junction communication by non-genotoxic carcinogens in rat liver in vivo. Toxicology, 238, 49-59.
122. Jeong, S.H. et al. (2000) Cadmium decreases gap junctional intercellular communication in mouse liver. Toxicol. Sci., 57, 156-166.
123. Gagliano, N. et al. (2006) Early cytotoxic effects of ochratoxin A in rat liver: a morphological, biochemical and molecular study. Toxicology, 225, 214-224.
124. Ren, P. et al. (1998) Inhibition of gap junctional intercellular communication by tumor promoters in connexin43 and connexin32- expressing liver cells: cell specificity and role of protein kinase C. Carcinogenesis, 19, 169-175.
125. Horvath, A. et al. (2002) Determination of the epigenetic effects of ochratoxin in a human kidney and a rat liver epithelial cell line. Toxicon, 40, 273-282.
126. Upham, B.L. et al. (2008) Tumor promoting properties of a cigarette smoke prevalent polycyclic aromatic hydrocarbon as indicated by the inhibition of gap junctional intercellular communication via phosphatidylcholine-specific phospholipase C. Cancer Sci., 99, 696-705.
127. Upham, B.L. et al. (2009) Structure-activity-dependent regulation of cell communication by perfluorinated fatty acids using in vivo and in vitro model systems. Environ. Health Perspect., 117, 545-551.
128. Machala, M. et al. (2003) Inhibition of gap junctional intercellular communication by noncoplanar polychlorinated biphenyls: inhibitory potencies and screening for potential mode(s) of action. Toxicol. Sci., 76, 102-111.
129. Matesic, D.F. et al. (1994) Changes in gap-junction permeability, phosphorylation, and number mediated by phorbol ester and nonphorbol- ester tumor promoters in rat liver epithelial cells. Mol. Carcinog., 10, 226-236.
130. Leithe, E. et al. (2004) Ubiquitination and down-regulation of gap junction protein connexin-43 in response to 12-O-tetradecanoylphorbol 13-acetate treatment. J. Biol. Chem., 279, 50089-50096.
131. Rivedal, E. et al. (2005) Connexin43 synthesis, phosphorylation, and degradation in regulation of transient inhibition of gap junction intercellular communication by the phorbol ester TPA in rat liver epithelial cells. Exp. Cell Res., 302, 143-152.
132. Guan, X. et al. (1996) Gap junction endocytosis and lysosomal degradation of connexin43-P2 in WB-F344 rat liver epithelial cells treated with DDT and lindane. Carcinogenesis, 17, 1791-1798.
133. Šimečková P, Vondráček J, Andrysík Z et al. The 2,2',4,4',5,5'-hexachlorobiphenyl- enhanced degradation of connexin 43 involves both proteasomal and lysosomal activities. Toxicol Sci 2009; 107: 9-18.
134. Gakhar, G. et al. (2009) Regulation of gap junctional intercellular communication by TCDD in HMEC and MCF-7 breast cancer cells. Toxicol. Appl. Pharmacol., 235, 171-181.
135. Sai, K. et al. (1998) Inhibitory effect of pentachlorophenol on gap junctional intercellular communication in rat liver epithelial cells in vitro. Cancer Lett., 130, 9-17.
136. Polyak, K. et al. (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev., 8, 9-22.
137. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
138. Lieberman, M.A. et al. (1981) Density-dependent regulation of cell growth: an example of a cell-cell recognition phenomenon. J. Membr. Biol., 63, 1-11.
139. Halbleib, J.M. et al. (2006) Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev., 20, 3199-3214.
140. Dietrich, C. et al. (1997) Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts. Oncogene, 15, 2743-2747.
141. Kato, A. et al. (1997) Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition. J. Biol. Chem., 272, 8065-8070.
142. Levenberg, S. et al. (1999) p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene, 18, 869-876.
143. Deffie, A. et al. (1995) Cyclin E restores p53 activity in contact-inhibited cells. Mol. Cell. Biol., 15, 3926-3933.
144. Swat, A. et al. (2009) Cell density-dependent inhibition of epidermal growth factor receptor signaling by p38alpha mitogen-activated protein kinase via Sprouty2 downregulation. Mol. Cell. Biol., 29, 3332-3343.
145. Ewen, M.E. et al. (1993) TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell, 74, 1009-1020.
146. Grazia Lampugnani, M. et al. (2003) Contact inhibition of VEGFinduced proliferation requires vascular endothelial cadherin, betacatenin, and the phosphatase DEP-1/CD148. J. Cell Biol., 161, 793-804.
147. Wang, C.Z. et al. (2009) DDR1/E-cadherin complex regulates the activation of DDR1 and cell spreading. Am. J. Physiol. Cell Physiol., 297, C419-C429.
148. Shen, Y. et al. (2007) SRC utilizes Cas to block gap junctional communication mediated by connexin43. J. Biol. Chem., 282, 18914-18921.
149. Alexander, D.B. et al. (2004) Normal cells control the growth of neighboring transformed cells independent of gap junctional communication and SRC activity. Cancer Res., 64, 1347-1358.
150. Rubin, H. (2008) Contact interactions between cells that suppress neoplastic development: can they also explain metastatic dormancy? Adv. Cancer Res., 100, 159-202.
151. Li, X. et al. (2009) Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration. Oncogene, 28, 4272-4283.
152. Jhon Alberto Ochoa-Alvarez CG et al. (2011) Goldberg contact normalization: mechanisms and pathways to biomarkers and chemotherapeutic targets. In Extracellular and intracellular signaling. RSC Publishing, pp. 105-115.
153. Panse, J. et al. (1997) Fibroblasts transformed by chemical carcinogens are sensitive to intercellular induction of apoptosis: implications for the control of oncogenesis. Carcinogenesis, 18, 259-264.
154. Krishnan, H. et al. (2012) SRC points the way to biomarkers and chemotherapeutic targets. Genes Cancer, 3, 426-435.
155. Oesch, F. et al. (1988) 12-O-tetradecanoylphorbol-13-acetate releases human diploid fibroblasts from contact-dependent inhibition of growth. Carcinogenesis, 9, 1319-1322.
156. Dietrich, C. et al. (2010) The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis, 31, 1319-1328.
157. Barouki, R. et al. (2007) The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett., 581, 3608-3615.
158. Kung, T. et al. (2009) The aryl hydrocarbon receptor (AhR) pathway as a regulatory pathway for cell adhesion and matrix metabolism. Biochem. Pharmacol., 77, 536-546.
159. Andrysík, Z. et al. (2007) The aryl hydrocarbon receptor-dependent deregulation of cell cycle control induced by polycyclic aromatic hydrocarbons in rat liver epithelial cells. Mutat. Res., 615, 87-97.
160. Weiss, C. et al. (2008) TCDD deregulates contact inhibition in rat liver oval cells via Ah receptor, JunD and cyclin A. Oncogene, 27, 2198-2207.
161. Andrysík, Z. et al. (2013) Aryl hydrocarbon receptor-mediated disruption of contact inhibition is associated with connexin43 downregulation and inhibition of gap junctional intercellular communication. Arch. Toxicol., 87, 491-503.
162. Andersson, H. et al. (2012) Proangiogenic effects of environmentally relevant levels of bisphenol A in human primary endothelial cells. Arch. Toxicol., 86, 465-474.
163. Li, M.W. et al. (2010) Connexin 43 is critical to maintain the homeostasis of the blood-testis barrier via its effects on tight junction reassembly. Proc. Natl. Acad. Sci. U. S. A., 107, 17998-18003.
164. Lin, Z.X. et al. (1986) Inhibition of gap junctional intercellular communication in human teratocarcinoma cells by organochlorine pesticides. Toxicol. Appl. Pharmacol., 83, 10-19.
165. Ruch, R.J. et al. (1987) Inhibition of intercellular communication between mouse hepatocytes by tumor promoters. Toxicol. Appl. Pharmacol., 87, 111-120.
166. Liu, J. et al. (2015) Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett., 356, 197-203.
167. Ravi, R. et al. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev., 14, 34-44.
168. Hanel, W. et al. (2012) Links between mutant p53 and genomic instability. J. Cell. Biochem., 113, 433-439.
169. Hacke, K. et al. (2010) Regulation of MCP-1 chemokine transcription by p53. Mol. Cancer, 9, 82.
170. Tang, X. et al. (2012) p53 is an important regulator of CCL2 gene expression. Curr. Mol. Med., 12, 929-943.
171. Wang, L. et al. (2011) PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 11, 248.
172. Chipuk, J.E. et al. (2006) Dissecting p53-dependent apoptosis. Cell Death Differ., 13, 994-1002.
173. Nicolay, B.N. et al. (2013) Loss of RBF1 changes glutamine catabolism. Genes Dev., 27, 182-196.
174. Gabellini, C. et al. (2006) Involvement of RB gene family in tumor angiogenesis. Oncogene, 25, 5326-5332.
175. Amato, A. et al. (2009) CENPA overexpression promotes genome instability in pRb-depleted human cells. Mol. Cancer, 8, 119.
176. Attardi, L.D. et al. (2013) RB goes mitochondrial. Genes Dev., 27, 975-979.
177. Guido, C. et al. (2012) Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production. Cell Cycle, 11, 3019-3035.
178. Geng, L. et al. (2013) TGF-beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis. PLoS One, 8, e59918.
179. Glick, A.B. et al. (1996) Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res., 56, 3645-3650.
180. Rao, C.V. et al. (2013) Genomic instability and colon carcinogenesis: from the perspective of genes. Front. Oncol., 3, 130.
181. Taylor, M.A. et al. (2011) Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr., 15, 117-132.
182. Mishra, S. et al. (2013) Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene.
183. Shackelford, D.B. (2013) Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressor. J. Carcinog., 12, 16.
184. Londesborough, A. et al. (2008) LKB1 in endothelial cells is required for angiogenesis and TGFbeta-mediated vascular smooth muscle cell recruitment. Development, 135, 2331-2338.
185. Forcet, C. et al. (2007) Dialogue between LKB1 and AMPK: a hot topic at the cellular pole. Sci. STKE, 2007, pe51.
186. Gurumurthy, S. et al. (2010) The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature, 468, 659-663.
187. Takeda, S. et al. (2007) LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. Anticancer Res., 27, 761-768.
188. Gatenby, R.A. et al. (2003) The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res., 63, 3847-3854.
189. Zhu, W. et al. (1997) Increased genetic stability of HeLa cells after connexin 43 gene transfection. Cancer Res., 57, 2148-2150.
190. Fiaschi, T. et al. (2012) Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res., 72, 5130-5140.
191. Gregory, S.H. et al. (1979) Glycolytic enzyme activities in malignant cells grown in vitro and in vivo. Cancer Lett., 7, 319-324.
192. Feyler, S. et al. (2012) Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One, 7, e35981.
193. González-Suárez, E. et al. (2002) Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol. Cell. Biol., 22, 7291-7301.
194. Li, H. et al. (1999) Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro. Oncogene, 18, 6785-6794.
195. Maniwa, Y. et al. (2001) Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer. Chest, 120, 589-594.
196. Lee, J.S. et al. (2014) A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1. Neuro. Oncol., 16, 191-203.
197. Goh, A.M. et al. (2011) The role of mutant p53 in human cancer. J. Pathol., 223, 116-126.
198. Cooks, T. et al. (2013) Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell, 23, 634-646.
199. Lorin, S. et al. (2013) Autophagy regulation and its role in cancer. Semin. Cancer Biol., 23, 361-379.
200. Rayess, H. et al. (2012) Cellular senescence and tumor suppressor gene p16. Int. J. Cancer, 130, 1715-1725.
201. Sperka, T. et al. (2012) DNA damage checkpoints in stem cells, ageing and cancer. Nat. Rev. Mol. Cell Biol., 13, 579-590.
202. Gore, A.J. et al. (2014) Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation. J. Clin. Invest., 124, 338-352.
203. Chou, N.H. et al. (2006) Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma. World J. Gastroenterol., 12, 7188-7191.
204. Ying, L. et al. (2005) Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. Cancer Res., 65, 9132-9136.
205. Mankame, T.P. et al. (2012) The RB tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7. Neoplasia, 14, 1213-1222.
206. Li, H. et al. (2006) Transforming growth factor beta suppresses human telomerase reverse transcriptase (hTERT) by Smad3 interactions with c-Myc and the hTERT gene. J. Biol. Chem., 281, 25588-25600.
207. Fabregat, I. et al. (2013) TGF-beta signaling in cancer treatment. Curr. Pharm. Des, 20, 2934-2947.
208. Hasegawa, T. et al. (2013) Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-β signaling. Int. J. Cancer.
209. Bierie, B. et al. (2010) Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev., 21, 49-59.
210. Bailey JM, Leach SD. (2012) Signaling pathways mediating epithelialmesenchymal crosstalk in pancreatic cancer: Hedgehog, Notch and TGFbeta. In Grippo PJ, Munshi HG (eds) Pancreatic cancer and tumor microenvironment. Trivandrum, India.
211. Sanchez-Cespedes, M. (2011) The role of LKB1 in lung cancer. Fam. Cancer, 10, 447-453.
212. Shackelford, D.B. et al. (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer, 9, 563-575.
213. Kline, E.R. et al. (2013) LKB1 represses focal adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulate FAK site maturation and directional persistence. J. Biol. Chem., 288, 17663-17674.
214. Xu, X. et al. (2013) LKB1 controls human bronchial epithelial morphogenesis through p114RhoGEF-dependent RhoA activation. Mol. Cell. Biol., 33, 2671-2682.
215. Wingo, S.N. et al. (2009) Somatic LKB1 mutations promote cervical cancer progression. PLoS One, 4, e5137.
216. Salem, A.F. et al. (2012) Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. Cell Cycle, 11, 2545-2556.
217. Spath, C. et al. (2013) Inverse relationship between tumor proliferation markers and connexin expression in a malignant cardiac tumor originating from mesenchymal stem cell engineered tissue in a rat in vivo model. Front. Pharmacol., 4, 42.
218. Ezumi, K. et al. (2008) Aberrant expression of connexin 26 is associated with lung metastasis of colorectal cancer. Clin. Cancer Res., 14, 677-684.
219. Ogawa, K. et al. (2012) Silencing of connexin 43 suppresses invasion, migration and lung metastasis of rat hepatocellular carcinoma cells. Cancer Sci., 103, 860-867.
220. Zhang, D. et al. (2012) Cx31.1 acts as a tumour suppressor in nonsmall cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis. J. Cell. Mol. Med., 16, 1047-1059.
221. Czyz, J. (2008) The stage-specific function of gap junctions during tumourigenesis. Cell. Mol. Biol. Lett., 13, 92-102.
222. Corn, P.G. (2012) The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag. Res., 4, 183-193.
223. Li, J.F. et al. (2014) The effects of cell compressibility, motility and contact inhibition on the growth of tumor cell clusters using the Cellular Potts Model. J. Theor. Biol., 343, 79-91.
224. Dixon, J.S. (1987) Short-term clinical trials of anti-rheumatoid drugs- an opinion. Agents Actions, 21, 89-92.
225. Schrader, J. et al. (2009) Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown. BMC Cancer, 9, 464.
226. WARBURG, O. (1956) On the origin of cancer cells. Science, 123, 309-314.
227. Shackelford, D.B. et al. (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer, 9, 563-575.
228. Andrade-Vieira, R. et al. (2013) Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways. PLoS One, 8, e56567.
229. Sen, N. et al. (2012) p53 and metabolism: old player in a new game. Transcription, 3, 119-123.
230. Zhang, C. et al. (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat. Commun., 4, 2935.
231. Dasgupta, B. et al. (2009) AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev. Cell, 16, 256-270.
232. Liu, Y. et al. (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol. Cancer Ther., 11, 1672-1682.
233. Fillon, M. (2012) Getting it right: BPA and the difficulty proving environmental cancer risks. J. Natl. Cancer Inst., 104, 652-655.
234. Betancourt, A.M. et al. (2012) Altered carcinogenesis and proteome in mammary glands of rats after prepubertal exposures to the hormonally active chemicals bisphenol a and genistein. J. Nutr., 142, 1382S-1388S.
235. Durando, M. et al. (2011) Prenatal exposure to bisphenol A promotes angiogenesis and alters steroid-mediated responses in the mammary glands of cycling rats. J. Steroid Biochem. Mol. Biol., 127, 35-43.
236. Ptak, A. et al. (2012) Bisphenol A induces leptin receptor expression, creating more binding sites for leptin, and activates the JAK/Stat, MAPK/ERK and PI3K/Akt signalling pathways in human ovarian cancer cell. Toxicol. Lett., 210, 332-337.
237. Pupo, M. et al. (2012) Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer- associated fibroblasts. Environ. Health Perspect., 120, 1177-1182.
238. Goodson, W.H. 3rd et al. (2011) Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. Carcinogenesis, 32, 1724-1733.
239. Allard, P. et al. (2010) Bisphenol A impairs the double-strand break repair machinery in the germline and causes chromosome abnormalities. Proc. Natl. Acad. Sci. USA, 107, 20405-20410.
240. Ito, Y. et al. (2012) Identification of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a novel target of bisphenol A. PLoS One, 7, e50481.
241. Takahashi, A. et al. (2004) Bisphenol A from dental polycarbonate crown upregulates the expression of hTERT. J. Biomed. Mater. Res. B. Appl. Biomater., 71, 214-221.
242. Zhu, H. et al. (2010) Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells. Oncol. Rep., 23, 129-139.
243. Hassan, Z.K. et al. (2012) Bisphenol A induces hepatotoxicity through oxidative stress in rat model. Oxid. Med. Cell. Longev., 2012, 194829.
244. Bratton, M.R. et al. (2012) The organochlorine o,p'-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells. Environ. Health Perspect., 120, 1291-1296.
245. Yáñez, L. et al. (2004) DDT induces DNA damage in blood cells. Studies in vitro and in women chronically exposed to this insecticide. Environ. Res., 94, 18-24.
246. Hurd-Brown, T. et al. (2013) Effects of DDT and triclosan on tumorcell binding capacity and cell-surface protein expression of human natural killer cells. J. Appl. Toxicol., 33, 495-502.
247. Arce, G.T. et al. (2010) Genetic toxicology of folpet and captan. Crit. Rev. Toxicol., 40, 546-574.
248. Canal-Raffin, M. et al. (2008) Cytotoxicity of folpet fungicide on human bronchial epithelial cells. Toxicology, 249, 160-166.
249. Campos-Pereira, F.D. et al. (2012) Early cytotoxic and genotoxic effects of atrazine on Wistar rat liver: a morphological, immunohistochemical, biochemical, and molecular study. Ecotoxicol. Environ. Saf., 78, 170-177.
250. Pinchuk, L.M. et al. (2007) In vitro atrazine exposure affects the phenotypic and functional maturation of dendritic cells. Toxicol. Appl. Pharmacol., 223, 206-217.
251. Hou, L. et al. (2013) Lifetime pesticide use and telomere shortening among male pesticide applicators in the Agricultural Health Study. Environ. Health Perspect., 121, 919-924.
252. Jin, X.T. et al. (2014) Dichlorodiphenyltrichloroethane exposure induces the growth of hepatocellular carcinoma via Wnt/β-catenin pathway. Toxicol. Lett., 225, 158-166.
253. Han, E.H. et al. (2008) o,p'-DDT induces cyclooxygenase-2 gene expression in murine macrophages: Role of AP-1 and CRE promoter elements and PI3-kinase/Akt/MAPK signaling pathways. Toxicol. Appl. Pharmacol., 233, 333-342.
254. Gordon, E. et al. (2012) Folpet-induced short term cytotoxic and proliferative changes in the mouse duodenum. Toxicol. Mech. Methods, 22, 54-59.
255. Albanito, L. et al. (2008) G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ. Health Perspect., 116, 1648-1655.
256. Tsuda, H. et al. (2005) High susceptibility of human c-Ha-ras protooncogene transgenic rats to carcinogenesis: a cancer-prone animal model. Cancer Sci., 96, 309-316.
257. Ueda, M. et al. (2005) Possible enhancing effects of atrazine on growth of 7,12-dimethylbenz(a) anthracene-induced mammary tumors in ovariectomized Sprague-Dawley rats. Cancer Sci., 96, 19-25.
258. Wetzel, L.T. et al. (1994) Chronic effects of atrazine on estrus and mammary tumor formation in female Sprague-Dawley and Fischer 344 rats. J. Toxicol. Environ. Health, 43, 169-182.